BRENTUXIMAB VEDOTIN AND BENDAMUSTINE (BvB) IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: AN INTERNATIONAL, MULTICENTER, SINGLE-ARM, PHASE 1–2 TRIAL

BACKGROUND: The major objective of this study was to explore the safety and clinical activity of Brentuximab vedotin (Bv) and bendamustine in combination in patients with relapsed or refractory Hodgkin Lymphoma. Bv produces high response rates and durable progression-free survival (PFS) in CD30-expr...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Connor, Owen A., Lue, Jennifer K., Sawas, Ahmed, Amengual, Jennifer E., Deng, Changchun, Kalac, Matko, Falchi, Lorenzo, Marchi, Enrica, Ithamar, Turenne, Lichtenstein, Renee, Rojas, Celeste, Francescone, Mark, Schwartz, Lawrence, Cheng, Bin, Savage, Kerry J., Villa, Diego, Crump, Michael, Prica, Anca, Kukreti, Vishal, Cremers, Serge, Connors, Joseph M., Kurvuilla, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098158/
https://www.ncbi.nlm.nih.gov/pubmed/29276022
http://dx.doi.org/10.1016/S1470-2045(17)30912-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098158/
https://www.ncbi.nlm.nih.gov/pubmed/29276022
http://dx.doi.org/10.1016/S1470-2045(17)30912-9

Ejemplares similares